Zydus Healthcare Limited
Phone 022-62721700
AddressZydus Healthcare Limited,
Zydus Tower, CTS No. 460/6,
Village Pahadi. Off I.B. Patel Road,
Goregaon East, Mumbai - 400063
Empaglyn
- Zydus Xperia
- Diabetology
Empagliflozin was approved by USFDA in 2014 primarily for the management of Type 2 Diabetes Mellitus (T2DM) in adults. Empagliflozin is an inhibitor of the sodium-glucose co-transporter 2 (SGLT2) which reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion.
Brand Composition
- Empaglyn: Empagliflozin 10 mg/ 25 mg
- Empaglyn M: Empagliflozin 12.5 mg/ 25 mg + Metformin 1000 mg
- Empaglyn S: Empagliflozin 10 mg/ 25 mg + Sitagliptin 50 mg/ 100 mg
- Empaglyn L: Empagliflozin 10 mg/ 25 mg + Linagliptin 5 mg
Schedule H Prescription Drug. It should not be sold by retail without the prescription of a Registered Healthcare Practitioner.
Empagliflozin Usage
Empagliflozin is primarily used in T2DM management It has also been approved for use in heart failure and chronic kidney disease. Other pleotropic benefits include body weight reduction, decrease in blood pressure, beneficial effects in NASH (Nonalcoholic Steatohepatitis) and Cardiac remodelling